Theranib Inc. is a Nova Scotian biotech company pioneering precision first-in-class cancer therapies targeting ALDH1A3, a novel target to inhibit metastasis and therapy resistance in solid tumors including breast, lung, pancreatic, ovarian and brain cancers. Their approach combines novel small molecule drug design with a biomarker assay to identify cancer patients most likely to benefit from our drug, maximizing efficacy, and aiming to improve outcomes and investor returns.
We are delighted to work with your team!